Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Multicenter, Phase 1 Study to Evaluate the Maximum Tolerated Dose of Orally Administered CB-03-10 With Dose Expansion Phase, in Subjects With Advanced Solid Tumors

NCT03863145 is registered in ClinicalTrials.gov with Cosmo Technologies Ltd as lead sponsor.

NCT NCT03863145
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03863145 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Multicenter, Phase 1 Study to Evaluate the Maximum Tolerated Dose of Orally Administered CB-03-10 With Dose Expansion Phase, in Subjects With Advanced Solid Tumors
Lead sponsor
Cosmo Technologies Ltd
Phase
Phase 1
Overall status
Unknown status
Start date
June 14, 2022
Completion date
June 1, 2026
Enrollment
90 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced refractory solid tumors, subjects considered likely to respond to cb-03-10